**Pharmaceutical Products:** 70%
**Biotechnology:** 20%
**Research and Development:** 10%

**Top 3 Markets:**
**South Korea:** 50%
**China:** 30%
**USA:** 15%

Hanmi Pharm. Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, accounting for approximately 70% of total revenue. Another significant portion comes from biotechnology, followed by income from research and development.

The largest market for Hanmi Pharm. is South Korea, which represents half of the revenue. China and the USA are also important markets, together accounting for 45% of the revenue. These markets are crucial for the company's growth and expansion in the global pharmaceutical industry.

**Production Sites:** Seoul, South Korea; Pyeongtaek, South Korea; Hwaseong, South Korea

Hanmi Pharm. Co., Ltd. mainly produces its pharmaceutical products in South Korea. The main production facilities are located in Seoul, Pyeongtaek, and Hwaseong. These sites are strategically chosen to efficiently serve both the domestic and international markets. Hanmi Pharm continuously invests in modernizing and expanding its production capacities to meet the increasing demands of the global pharmaceutical industry.

**Focus on Research and Development:** 15% of revenue (2024)

**International Expansion:** New markets in Europe and North America (2024)

**Partnerships and Alliances:** Collaborations with global pharmaceutical companies (2024)

Hanmi Pharm. Co., Ltd. pursues a growth strategy that heavily emphasizes research and development. The company invests approximately 15% of its revenue in developing new drugs and technologies to expand its product pipeline and introduce innovative solutions to the market.

In addition, Hanmi Pharm focuses on international expansion, particularly in Europe and North America. These markets offer significant growth opportunities as the company aims to strengthen its presence outside of Asia.

Another key component of the growth strategy is partnerships and alliances with leading global pharmaceutical companies. These collaborations enable Hanmi Pharm to benefit from joint research projects and facilitate access to new technologies and markets.

**Main raw materials:** Pharmaceutical active ingredients, excipients

**Main importing countries:** USA, Germany, China, India

Hanmi Pharm. Co., Ltd. imports a variety of raw materials needed for the production of their pharmaceutical products. This includes especially pharmaceutical active ingredients and excipients that are essential for the manufacturing of medications.

The USA and Germany are important suppliers of high-quality pharmaceutical active ingredients, while China and India often serve as sources for more cost-effective raw materials and excipients. These countries are known for their strong pharmaceutical industries and offer a wide range of materials required for the production of medications.

**Market share in South Korea:** 10% (estimated, 2024)
**R&D investments:** 15% of revenue (2024)
**Patent portfolio:** Over 50 active patents (2024)

Hanmi Pharm. Co., Ltd. has a significant competitive advantage that consists of several factors. The company holds an estimated market share of 10% in the South Korean pharmaceutical market, indicating a strong local presence.

Another crucial factor is the high investment in research and development, which accounts for about 15% of revenue. These investments enable Hanmi Pharm to continuously develop and bring innovative products to the market, strengthening their competitiveness.

Additionally, the company has an extensive patent portfolio with over 50 active patents, providing them protection against imitators and further solidifying their market position. Together, these factors give Hanmi Pharm a sustainable competitive advantage in the industry.

**Institutional Investor Share:** approximately 45% (estimated for 2025)
**Insider Buys/Sells:** No significant transactions reported (2025)

The institutional investor share in Hanmi Pharm. Co., Ltd. is estimated to be around 45%. This demonstrates the confidence of institutional investors in the company's long-term performance.

Regarding insider buys or sells, no significant transactions are known for the year 2025. This could indicate that the management and other insiders are currently not making significant changes to their stake in the company, suggesting a stable internal assessment of the company's development.

These pieces of information are based on the latest available data and general market trends.

**Market share of Hanmi Pharm. Co., Ltd.:** 5.2% (2025, estimated)

**Top competitors and their market shares:**
1. **Samsung BioLogics Co., Ltd.:** 12.5%
2. **Celltrion, Inc.:** 11.3%
3. **SK Biopharmaceuticals Co., Ltd.:** 8.7%
4. **LG Chem, Ltd.:** 7.9%
5. **Hanmi Pharm. Co., Ltd.:** 5.2%
6. **GC Pharma:** 4.8%
7. **Daewoong Pharmaceutical Co., Ltd.:** 4.5%
8. **Yuhan Corporation:** 4.2%
9. **Dong-A ST Co., Ltd.:** 3.9%
10. **JW Pharmaceutical Corporation:** 3.5%

**Moat of Hanmi Pharm. Co., Ltd.:**

Hanmi Pharm. Co., Ltd. has built a solid moat through its strong R&D pipeline and innovative drug development. The company is known for its research in long-acting release technologies and has formed several significant partnerships with international pharmaceutical companies. These strategic alliances help strengthen its technological edge and market position.

Compared to competitors, especially Samsung BioLogics and Celltrion, which have substantial production capacities and global distribution networks, Hanmi Pharm. may be at a disadvantage in terms of economies of scale and international reach. However, specializing in innovative technologies and focusing on niche markets provides a significant advantage.

Overall, Hanmi Pharm. has a respectable moat, but it is challenged by the stronger global networks and production capacities of larger competitors. Continuous investment in research and development remains crucial to maintaining and expanding its competitive advantage.

**Revenue Growth:** 8.5% (2024)
**R&D Expenses:** 15% of revenue (2024)
**Market Share in Asia:** 10% (2024)

Hanmi Pharm. Co., Ltd. recorded a revenue growth of 8.5% in 2024, attributed to a strong product pipeline and successful market launches. The company continues to invest heavily in research and development, with 15% of revenue allocated to this area. This indicates a strategic focus on innovation and long-term growth.

The 10% market share in Asia demonstrates that Hanmi Pharm. has a significant presence in one of the fastest-growing pharmaceutical markets in the world. This position could be strengthened through further expansions and partnerships.

Overall, the strong R&D focus and solid market position suggest that Hanmi Pharm. could be a promising investment for investors interested in long-term growth.

**Dividend Yield:** 1.5% (estimated for 2025)

Hanmi Pharm. Co., Ltd. has regularly paid dividends in the past, albeit with a relatively low dividend yield compared to other companies in the industry. The company's payout policy is conservative, indicating that the company prefers to reinvest its profits in research and development as well as corporate growth.

The reliability of dividend payments is high, as the company has a stable financial foundation and has not made any dividend cuts in recent years. Analysts expect Hanmi Pharm. to maintain its dividend policy as long as the financial conditions remain stable.